These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38990101)

  • 1. Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma.
    Lozano E; Mena MP; Garrabou G; Cardús O; Díaz T; Moreno DF; Mañé-Pujol J; Oliver-Caldés A; Battram A; Tovar N; Cibeira MT; Rodríguez-Lobato LG; Bladé J; Fernández de Larrea C; Rosiñol L
    Clin Cancer Res; 2024 Sep; 30(17):3944-3955. PubMed ID: 38990101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma.
    Lozano E; Mena MP; Díaz T; Martin-Antonio B; León S; Rodríguez-Lobato LG; Oliver-Caldés A; Cibeira MT; Bladé J; Prat A; Rosiñol L; Fernández de Larrea C
    Clin Cancer Res; 2020 Sep; 26(17):4688-4698. PubMed ID: 32513837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.
    Minnie SA; Kuns RD; Gartlan KH; Zhang P; Wilkinson AN; Samson L; Guillerey C; Engwerda C; MacDonald KPA; Smyth MJ; Markey KA; Vuckovic S; Hill GR
    Blood; 2018 Oct; 132(16):1675-1688. PubMed ID: 30154111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT blockade repolarizes AML-associated TIGIT
    Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4
    Holder KA; Burt K; Grant MD
    Clin Transl Immunology; 2021; 10(10):e1348. PubMed ID: 34707863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.
    Hattori N; Kawaguchi Y; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Yanagisawa K; Saito B; Harada H; Nakamaki T
    Biol Blood Marrow Transplant; 2019 May; 25(5):861-867. PubMed ID: 30639819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
    Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
    Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
    [No Abstract]   [Full Text] [Related]  

  • 14. TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies.
    Hasan MF; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Eloriaga JE; Kumar S; Andersen BW; Copik AJ
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.
    Huang S; Zhao Y; Liao P; Wang J; Li Z; Tan J; Zha X; Chen S; Li Y; Zhong L
    Front Oncol; 2022; 12():1014904. PubMed ID: 36439426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 and TIGIT Are Highly Co-Expressed on CD8
    Xu L; Liu L; Yao D; Zeng X; Zhang Y; Lai J; Zhong J; Zha X; Zheng R; Lu Y; Li M; Jin Z; Hebbar Subramanyam S; Chen S; Huang X; Li Y
    Front Oncol; 2021; 11():686156. PubMed ID: 34490086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.
    Lee BH; Kim JH; Kang KW; Lee SR; Park Y; Sung HJ; Kim BS
    Biomedicines; 2022 May; 10(5):. PubMed ID: 35625835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
    Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
    J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT immune checkpoint blockade restores CD8
    Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
    Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perturbed CD8
    Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
    Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.